Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer
Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to identify the group of women with early stage breast
cancer most likely to benefit from treatment with the selective progesterone receptor
modulator (SPRM) mifepristone. This will be done by treating women briefly prior to planned
surgery and examining the decrease in growth rate (measured by Ki-67 immunohistochemistry) in
tumor samples taken before and after exposure to mifepristone.